Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.

A series of isatin derivatives were synthesized and tested against SARS CoV 3C-like protease. Substitutions at the N-1 and C-5 positions were examined to elucidate the differences in substrate binding sites of the rhinovirus 3C protease and SARS CoV 3C-like protease. Compound 5f shows significant inhibition with an IC(50) of 0.37 microM. Further study showed that, unlike the irreversible covalent binding of isatin derivatives to human rhinovirus 3C protease, the compounds tested in this study are all noncovalent reversible inhibitors.

[1]  H. Hsieh,et al.  Evaluation of metal‐conjugated compounds as inhibitors of 3CL protease of SARS‐CoV , 2004, FEBS Letters.

[2]  A. Velázquez‐Campoy,et al.  Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. , 2004, Biochemistry.

[3]  Kuo-Chen Chou,et al.  Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS , 2003, Biochemical and Biophysical Research Communications.

[4]  Peter Cameron,et al.  A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[5]  D. Matthews,et al.  Design , Synthesis , and Evaluation of Nonpeptidic Inhibitors of Human Rhinovirus 3 C Protease , 2022 .

[6]  Eric D. Brown,et al.  High-Throughput Screening Identifies Inhibitors of the SARS Coronavirus Main Proteinase , 2004, Chemistry & Biology.

[7]  Y. Liu,et al.  3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism. , 2004, Biochemistry.

[8]  Christian Drosten,et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[9]  Chi‐Huey Wong,et al.  Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease. , 2005, Journal of medicinal chemistry.

[10]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[11]  Herman Tse,et al.  Identification of Novel Small-Molecule Inhibitors of Severe Acute Respiratory Syndrome-Associated Coronavirus by Chemical Genetics , 2004, Chemistry & Biology.

[12]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[13]  G. Gao,et al.  The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  N. Stiefl,et al.  A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods. , 2005, Journal of medicinal chemistry.

[15]  Hsuan-Cheng Huang,et al.  Small molecules targeting severe acute respiratory syndrome human coronavirus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Luhua Lai,et al.  Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase* , 2004, Journal of Biological Chemistry.

[17]  Ying-Ta Wu,et al.  Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors , 2005, Bioorganic & Medicinal Chemistry Letters.

[18]  J. A. Comer,et al.  A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[19]  Luhua Lai,et al.  SCORE: A New Empirical Method for Estimating the Binding Affinity of a Protein-Ligand Complex , 1998 .

[20]  Rolf Hilgenfeld,et al.  Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs , 2003, Science.